You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PI3KCD

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Novel Genetic Disorders of the Immune System

Recruiting
  • PI3KCD
  • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Cushing Disease Trial (Fimepinostat)

    Not yet recruiting
    • Cushing Disease
    • (no location specified)
    Jul 31, 2023

    Improving Prostate Lesion Classification and Development

    Completed
    • Prostate Cancer
      • Nuernberg, Germany
        Department of Radiology and Nuclear Medicine, Klinikum Nuernberg
      Nov 2, 2023

      Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)

      Recruiting
      • Endometrial Cancer
      • Ovarian Cancer
      • Houston, Texas
        M D Anderson Cancer Center
      Sep 27, 2022

      Alzheimer Trial in Hialeah, Maitland, Winter Park ([18F]PI-2620)

      Recruiting
      • Alzheimer Disease
      • Hialeah, Florida
      • +2 more
      Jan 18, 2023

      Urinary Tract Infection, Acute Pyelonephritis Trial (TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion)

      Not yet recruiting
      • Urinary Tract Infection
      • Acute Pyelonephritis
      • (no location specified)
      Sep 22, 2023

      Advanced Cancers, Solid Tumors Trial in Houston (Pazopanib, Everolimus)

      Active, not recruiting
      • Advanced Cancers
      • Solid Tumors
      • Houston, Texas
        University of Texas MD Anderson Cancer Center
      Dec 16, 2022

      Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial in Zhoukou, Tianjin (Linperlisib)

      Not yet recruiting
      • Relapsed/Refractory Large Granular T Lymphocytic Leukemia
      • Zhoukou, Henan, China
      • +1 more
      Dec 22, 2022

      Hyperglycemia Drug Induced Trial in Durham (REMD-477)

      Terminated
      • Hyperglycemia Drug Induced
      • REMD-477
      • Durham, North Carolina
        Duke University Medical Center
      Nov 4, 2022

      Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

      Not yet recruiting
      • Breast Cancer
      • +3 more
      • Miami, Florida
        University of Miami
      Apr 12, 2023

      Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment Trial in Zhoukou, Tianjin (Linperlisib)

      Not yet recruiting
      • Autoimmune Hemolytic Anemia
      • Failure of Two Rounds of Treatment
      • Zhoukou, Henan, China
      • +1 more
      Jan 7, 2023

      PIK3CA Mutation-Related Tumors Trial in Shanghai (WX390)

      Completed
      • PIK3CA Mutation-Related Tumors
      • Shanghai, Shanghai, China
        Shanghai East Hospital
      Nov 9, 2023

      Metastatic Breast Cancer Trial in East Melbourne (BYl719)

      Completed
      • Metastatic Breast Cancer
      • East Melbourne, Victoria, Australia
        Peter MacCallum Cancer Centre
      Aug 11, 2022

      Bile Acids in Acute Insulin Resistance

      Recruiting
      • PI3K Gene Mutation
      • +4 more
      • Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
      • New York, New York
        Columbia University Medical Center
      Oct 6, 2022

      Estrogen Receptor-positive Breast Cancer Trial in Nashville (2-Week Ketogenic Diet, Letrozole)

      Recruiting
      • Estrogen Receptor-positive Breast Cancer
      • Nashville, Tennessee
        Vanderbilt-Ingram Cancer Center
      Sep 20, 2022

      Leukemia, Acute Lymphocytic Trial in Durham (Copanlisib)

      Recruiting
      • Leukemia, Acute Lymphocytic
      • Durham, North Carolina
        Duke Cancer Center
      Jun 28, 2022

      Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)

      Not yet recruiting
      • Metastatic Breast Cancer
      • +3 more
      • (no location specified)
      Aug 18, 2022

      Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (GSK2636771, Pembrolizumab)

      Active, not recruiting
      • Melanoma and Other Malignant Neoplasms of Skin
      • Metastatic Melanoma
      • Houston, Texas
        University of Texas MD Anderson Cancer Center
      Sep 22, 2022

      Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)

      Recruiting
      • Lung Cancer Squamous Cell
      • +3 more
      • Boston, Massachusetts
      • +2 more
      Jan 9, 2023

      Mantle Cell Lymphoma Trial (parsaclisib, rituximab, bendamustine)

      Withdrawn
      • Mantle Cell Lymphoma
      • (no location specified)
      Apr 22, 2022

      HER2-positive Breast Cancer Trial (Inavolisib, PHESGO, Endocrine therapy)

      Not yet recruiting
      • HER2-positive Breast Cancer
      • (no location specified)
      Mar 23, 2022

      Patients With Cognitive and Behavioral Disorders

      Not yet recruiting
      • Behavioral Variant of Frontotemporal Disorder (bvFTD)
      • +3 more
      • Submission of the NEO-PI-3 questionnaire
      • Submission of the Interpersonal Reactivity Index questionnaire (IRI)
      • (no location specified)
      Sep 29, 2023

      dapted Strategy Including Magnetic Resonance Imaging and

      Completed
      • Prostate Cancer
      • Prostate Adenocarcinoma
        • Ankara, Turkey
          Ankara University School of Medicine
        Sep 6, 2023

        PI3Kd Inhibitor, Parsaclisib, CHOP Trial (Parsaclisib, CHOP)

        Not yet recruiting
        • PI3Kδ Inhibitor
        • +3 more
        • (no location specified)
        Feb 10, 2022

        Advanced Solid Tumor Trial in Sutton, Manchester (SL-901)

        Recruiting
        • Advanced Solid Tumor
        • Sutton, Surrey, United Kingdom
        • +1 more
        May 16, 2022